U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
🤖 D.R.A.F.T. Summary
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease Results from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma SAN CARLOS, Calif. — BeOne Medicines Ltd.
Outlets covering this story
Montreal Gazette
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →